<SEC-DOCUMENT>0001654954-23-009256.txt : 20230717
<SEC-HEADER>0001654954-23-009256.hdr.sgml : 20230717
<ACCEPTANCE-DATETIME>20230717140846
ACCESSION NUMBER:		0001654954-23-009256
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230717
FILED AS OF DATE:		20230717
DATE AS OF CHANGE:		20230717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		231091296

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a2876g.htm
<DESCRIPTION>BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2023 Issuer Direct Corporation -->
<title>a2876g</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr style="background-color: #ffffff">
<td style="vertical-align: top; width: 100%"><br></td>
</tr></table>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 6-K</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Report
of Foreign Issuer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Rule 13a-16 or 15d-16 of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of July 2023</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: 001-11960</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1
Francis Crick Avenue</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
Biomedical Campus</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
CB2 0AA</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">United
Kingdom</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F X&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
&#xA0; &#xA0; &#xA0; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Form 40-F
__</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Yes
__&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; &#xA0;&#xA0;
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; No X</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If
&#x201C;Yes&#x201D; is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">INDEX
TO EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">1.
Beyfortus approved in US for infant RSV prevention</font>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">17
July&#xA0;2023</font>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Beyfortus approved in the US for the prevention of RSV</font></div>
<div style="text-align: center"><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
lower respiratory tract disease in infants</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center"><font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
First preventive option specifically designed to
protect</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font><font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">the
broad infant population through its first RSV season</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Across all clinical endpoints, a single dose of Beyfortus delivered
consistent and</font><br></font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
sustained efficacy against RSV disease vs
placebo</font>&#xA0;<br></font></div>
<br>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">AstraZeneca and Sanofi's&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;(nirsevimab) has been approved in the US for
the prevention of respiratory syncytial virus (RSV) lower
respiratory tract disease (LRTD) in newborns and infants born
during or entering their first RSV season, and for children up to
24 months of age who remain vulnerable to severe RSV disease
through their second RSV season.&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;will be available in the US ahead of the
upcoming 2023-2024 RSV&#xA0;season.</font></font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The
approval by the Food and Drug Administration (FDA) follows
the&#xA0;</font><font style="text-decoration: underline; color: #0000FF">unanimous</font><font style="color: #000000">&#xA0;vote
by the Antimicrobial Drugs Advisory Committee (AMDAC) on the
favourable benefit-risk profile of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">, and was based on the extensive clinical
development programme for&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">spanning three pivotal late-stage clinical trials.
Across all clinical endpoints, a single dose
of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;demonstrated consistent efficacy against RSV
LRTD extending through five months, the duration of a typical RSV
season.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1-4</font></font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;is the first preventive option approved to
protect a broad infant population, including those born healthy at
term, or preterm, or with specific health conditions that make them
vulnerable to severe RSV disease. The single dose can be flexibly
administered at the beginning of the RSV season or at birth for
those born during the RSV season.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Iskra Reic, Executive Vice President, Vaccines and
Immune Therapies, AstraZeneca, said: "</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;represents an opportunity for a
paradigm-shift in preventing serious respiratory disease due to RSV
across a broad infant population in the US. The science
that&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;is built on demonstrates AstraZeneca's
continued leadership in addressing the needs of the most vulnerable
populations and reducing the burden on
healthcare&#xA0;systems."</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Thomas Triomphe, Executive Vice President,
Vaccines, Sanofi, said: "Today's approval marks an unprecedented
moment for protecting infant health in the U.S., following an RSV
season that took a record toll on infants, their families, and the
U.S. healthcare system.&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;is the only monoclonal antibody approved for
passive immunisation&#xA0; to provide safe and effective protection
for all infants during their first RSV season. I am proud that, by
prioritising this potential game-changer, we are now about to
bring&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;to American families."</font></font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 71px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">RSV is the leading cause of hospitalisation for
infants under the age of one in the US, averaging 16 times higher
than the annual rate for influenza.</font><font style="font-size: 70%; vertical-align: top; color: #000000">5,6</font><font style="color: #000000">&#xA0;Each
year, an estimated 590,000 RSV disease cases in infants under one
require medical care, including physician office, urgent care,
emergency room visits and hospitalisations.</font><font style="font-size: 70%; vertical-align: top; color: #000000">7</font></font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;was generally well tolerated with a
favourable safety profile that was consistent across all clinical
trials. The overall rates of adverse events were comparable
between&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">and placebo and the majority of adverse events
were mild or moderate in severity. The most common adverse events
were rash and injection site reactions.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1-4</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;was approved in the European Union in
October 2022 for the prevention of RSV LRTD in newborns and infants
during their first RSV season. Regulatory applications are also
currently under review in China, Japan and several other
countries.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
&#xA0;</font></div>
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">Notes</font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">RSV</font>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">RSV is a very contagious virus that can lead to
serious respiratory illness for infants, according to the Centers
for Disease Control and Prevention (CDC). RSV symptoms can include
runny nose, coughing, sneezing, fever, decrease in appetite, and
wheezing.</font><font style="font-size: 70%; vertical-align: top; color: #000000">8</font><font style="color: #000000">&#xA0;Two
out of three infants are infected with RSV during their first year
of life and almost all infants are infected by their second
birthday.</font><font style="font-size: 70%; vertical-align: top; color: #000000">8,9</font><font style="color: #000000">&#xA0;In
the US, RSV is the leading cause of hospitalisation in infants
under 12 months, averaging 16 times higher than the annual rate for
influenza.</font><font style="font-size: 70%; vertical-align: top; color: #000000">5,6</font><font style="color: #000000">&#xA0;Approximately
75% of infants hospitalised for RSV were born at term with no
underlying conditions in a study conducted from
2014-2015.</font><font style="font-size: 70%; vertical-align: top; color: #000000">10</font><font style="color: #000000">&#xA0;Each
year in the US, an estimated 590,000 RSV disease cases in infants
under one require medical care, including physician office, urgent
care, emergency room visits and
hospitalisations.</font><font style="font-size: 70%; vertical-align: top; color: #000000">7</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">Beyfortus</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Beyfortus</font><font style="color: #000000">&#xA0;(nirsevimab) is
a single dose long-acting antibody, developed and commercialised in
partnership by AstraZeneca and Sanofi using AstraZeneca's YTE
technology. It is designed to protect infants born during or
entering their first RSV season and for children up to 24 months of
age who remain vulnerable to severe RSV disease through their
second RSV season.&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus,</font><font style="color: #000000">provided directly to newborns and infants as a
single dose, offers rapid protection via an antibody to help
prevent LRTD caused by RSV, without requiring activation of the
immune system.&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;administration can be timed to the start of
the RSV season.</font><font style="font-size: 70%; vertical-align: top; color: #000000">11</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">has been granted regulatory designations to
facilitate expedited development by several major regulatory
agencies around the world. These include Breakthrough Therapy
Designation and Priority Review Designation by the China Center for
Drug Evaluation under the National Medical Products
Administration;&#xA0;</font><font style="text-decoration: underline; color: #0000FF">Breakthrough
Therapy</font><font style="color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">Designation</font><font style="color: #000000">&#xA0;from
the US Food and Drug Administration; access granted to the European
Medicines Agency (EMA&#xA0;</font><font style="text-decoration: underline; color: #0000FF">PRIority
MEdicines</font><font style="color: #000000">&#xA0;(PRIME) scheme;
and named "a medicine for prioritized development" under the
Project for Drug Selection to Promote New Drug Development in
Pediatrics by the Japan Agency for Medical Research and
Development&#xA0;(AMED).</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Pivotal clinical&#xA0;trials</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The Phase IIb (Trial 03) study was a randomised,
placebo-controlled trial designed to measure the efficacy
of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;against medically attended (MA) Lower
Respiratory Tract Infection (LRTI) through 150 days post-dose.
Healthy preterm infants of 29 to less than 35 weeks' gestational
age were randomised (2:1) to receive a single 50mg intramuscular
injection of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">or placebo regardless of
weight.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">dosing regimen was determined based on further
exploration of the Phase IIb data and was used in subsequent trials
as a single 50 mg dose for those who weigh less than 5 kg, or a
single 100 mg dose for those who weigh 5 kg or
greater.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The MELODY Phase III study (Trial 04) was a
randomised, double-blind, placebo- controlled trial conducted
across 21 countries designed to determine efficacy
of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;against medically attended LRTI due to
through 150 days after dosing, versus placebo, in healthy term and
late preterm infants (35 weeks gestational age or greater) entering
their first RSV season.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1,2,12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">MEDLEY (Trial 05) was a Phase II/III, randomised,
double-blind,&#xA0;</font><font style="font-style: italic; color: #000000">Synagis</font><font style="color: #000000">-controlled trial with the primary objective of
assessing safety and tolerability for&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">in preterm infants of less than 35 weeks
gestational age and infants with congenital heart disease (CHD)
and/or chronic lung disease of prematurity (CLD) eligible to
receive&#xA0;</font><font style="font-style: italic; color: #000000">Synagis</font><font style="color: #000000">.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4,12</font><font style="color: #000000">&#xA0;Between
July 2019 and May 2021 a total of 925 infants entering their first
RSV season were randomised to receive&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;or&#xA0;</font><font style="font-style: italic; color: #000000">Synagis</font><font style="color: #000000">. Safety was assessed by monitoring the occurrence
of adverse events through 360 days post-dose. Serum levels
of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;following dosing (on day 151) in this trial
were comparable with those observed in the MELODY Phase III trial,
indicating similar protection in this population to that in the
healthy term and late preterm infants is likely. Data were
published in the&#xA0;</font><font style="font-style: italic; text-decoration: underline; color: #0000FF">New
England Journal of Medicine (NEJM)</font><font style="color: #000000">&#xA0;in March 2022.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4,12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The
safety profile of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;was similar to&#xA0;</font><font style="font-style: italic; color: #000000">Synagis</font><font style="color: #000000">&#xA0;in the MEDLEY Phase II/III trial and
consistent with the safety profile in healthy term and preterm
infants studied in the MELODY and Phase IIb trials. While uncommon,
the most reported adverse reactions were: rash 14 days post-dose,
(the majority of which were mild to moderate; non-serious injection
site reactions within 7 days post-dose</font><font style="color: #000000; font-size: 13px">.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1,2,4,12</font></font>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
&#xA0;</font></div>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The results of MELODY, MEDLEY Phase II/III and the
Phase IIb trials demonstrate that a single dose of nirsevimab helps
protect infants during their first RSV season against RSV disease.
This broad infant population includes healthy term, late preterm
and preterm infants, as well as infants with specific health
conditions that make them vulnerable to severe RSV
disease.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1-4,12</font></font>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="color: #000000; font-family: Times New Roman; font-size: 13px">These
trials formed the basis of regulatory submissions which began
in&#xA0;2022.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
</font><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">Results
from the MELODY Phase III trial (Trial&#xA0;04)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The primary endpoint of the MELODY Phase III trial was met,
reducing the incidence of medically attended LRTI, such as
bronchiolitis or pneumonia, caused by RSV by 74.9%</font>
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">(95% CI 50.6, 87.3; P&lt;0.001) compared to
placebo.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1,2</font><font style="color: #000000">&#xA0;Observed
events were 1.2% in treatment arm vs 5% in placebo arm. The
efficacy of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;against the secondary endpoint of
hospitalisation was 60.2% (95% CI: -14.6, 86.2). Observed events
were 0.6% in treatment arm vs 1.6% in placebo arm. Between July
2019 and March 2020, 1,490 infants were randomised to receive
either nirsevimab or placebo at the RSV season start Initial data
from the MELODY Primary Cohort were published
in&#xA0;</font><font style="font-style: italic; text-decoration: underline; color: #0000FF">NEJM</font><font style="color: #000000">&#xA0;in
March 2022&#xA0;</font><font style="font-size: 70%; vertical-align: top; color: #000000">12</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">Results
from the Phase IIb trial (Trial&#xA0;03)</font>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">The primary endpoint of the Phase IIb study was
met, reducing the incidence of medically attended LRTI caused by
RSV by 70.1% (95% CI: 52.3, 81.2) compared to placebo. Observed
events were 2.6% in treatment arm vs 9.5% in placebo arm. Between
November 2016 and December 2017, 1,453 infants were randomised
(</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">, n=969; placebo, n=484) at the RSV season start.
Research was conducted by AstraZeneca in both hemispheres, at 164
sites in 23 countries. Data were published
in&#xA0;</font><font style="font-style: italic; text-decoration: underline; color: #0000FF">NEJM</font><font style="color: #000000">&#xA0;in
July&#xA0;2020.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In
a prespecified secondary endpoint,&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">reduced medically attended RSV LRTI with
hospitalisation by 78.4% (95% CI 51.9, 90.3) versus placebo.
Observed events were 0.8% in treatment arm vs 4.1% in placebo
arm.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,12</font><font style="color: #000000">&#xA0;A
post-hoc analysis of the Phase IIb study that applied the
recommended 50 mg dose in a subgroup of infants weighing less than
5 kg showed the efficacy of&#xA0;</font><font style="font-style: italic; color: #000000">Beyfortus</font><font style="color: #000000">&#xA0;against medically attended RSV LRTI and
medically attended RSV LRTI with hospitalisation was 86.2% (95% CI
68.0, 94.0) and 86.5% (95% CI 53.5,
96.1),&#xA0;respectively.</font><font style="font-size: 70%; vertical-align: top; color: #000000">12</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
&#xA0;</font></div>
<div><font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Sanofi&#xA0;Alliance</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In March 2017, AstraZeneca and
Sanofi&#xA0;</font><font style="text-decoration: underline; color: #0000FF">announced</font><font style="color: #000000">&#xA0;an
agreement to develop and commercialise nirsevimab. Under the terms
of the agreement, AstraZeneca leads development and manufacturing
activities, and Sanofi leads commercialisation activities and
records revenue. The two companies share costs and profits in all
territories except the US. AstraZeneca's revenue from the agreement
is reported as Alliance Revenue and Collaboration Revenue in the
Company's financial statements. Following
a&#xA0;</font><font style="text-decoration: underline; color: #0000FF">revision</font><font style="color: #000000">&#xA0;to
the profit-sharing arrangement relating to the development and
commercialisation of nirsevimab in the US between AstraZeneca,
Sanofi and Sobi, Sobi has entered into a direct relationship with
Sanofi, replacing the previous participation agreement with
AstraZeneca entered into in&#xA0;</font><font style="text-decoration: underline; color: #0000FF">November</font><font style="color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">2018</font><font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">AstraZeneca</font>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal &amp; Metabolism, and Respiratory
&amp; Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit&#xA0;</font><font style="text-decoration: underline; color: #0000FF">astrazeneca.com</font><font style="color: #000000">&#xA0;and
follow the Company on Twitter&#xA0;</font><font style="text-decoration: underline; color: #0000FF">@AstraZeneca</font><font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Contacts</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">For details on how to contact the Investor
Relations Team, please click</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.
For Media contacts, click</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">References</font>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Muller
WJ, et al. Nirsevimab for Prevention of RSV in Term and
Late-Preterm Infants. N Engl J Med. April 5, 2023. DOI:
10.1056/NEJMc2214773</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">2.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Hammitt
LL, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm
and Term Infants. N Engl J Med. 2022;386 (9): 837-846. Doi:
10.1056/NEJMoa2110275.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">3.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Griffin
P, MD et al. Single-Dose Nirsevimab for Prevention of RSV in
Preterm Infants. N Engl J Med. 2020;383: 415-425. DOI:
10.1056/NEJMoa1913556.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">4.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Domachowske
J, MD et al. Safety of Nirsevimab for RSV in Infants with Heart or
Lung Disease or Prematurity. N Engl J Med. 2022; 386
(9).</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">5.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Leader
S, Kohlhase K. Recent trends in severe respiratory syncytial virus
(RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5
Suppl):S127-S132. Doi:10.1067/s0022-3476(03)00510-9.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">6.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Zhou
H, et al. Hospitalizations associated with influenza and
respiratory syncytial virus in the United States, 1993-2008. Clin
Infect Dis. 2012 ;54 :1427-1436.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">7.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Rainisch
G, et al. Estimating the impact of multiple immunization products
on medically- attended respiratory syncytial virus (RSV) infections
in infants. Vaccine. 2020;38(2):251-257. <font style="color: rgb(0, 0, 0); font-family: Arial, 'sans-serif'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: -24.0667px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">
S127-S132. Doi:10.1067/s0022-</font></font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">Centers for Disease Control and
Prevention. RSV in Infants and Young Children. October 28, 2022.
https://</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">www.cdc.gov/rsv/high-risk/infants-young-children.html.</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">Accessed
July 2023.</font></font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">9.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Walsh,
EE. Respiratory Syncytial Virus infection: an illness for all ages.
Clin Chest Med. 2017; 38(1):29-36.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">10.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Esposito
S, et al. RSV Prevention in All Infants: Which Is the Most
Preferable Strategy? Front Immunol. 2022; 13: 880368. doi:
10.3389/fimmu.2022.880368.</font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">11.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">Centers for Disease Control and
Prevention. Vaccines &amp; Immunizations. August 18, 2017.
https:</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">//w</font><font style="color: #000000; font-size: 13px">ww</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">.cdc.gov/vaccines/vac-gen/immunity-types.htm.</font><font style="color: #000000">&#xA0;</font><font style="color: #000000; font-size: 13px">Accessed
July 2023.</font></font></div>
</div>
</div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">12.</font></div>
<div style="text-align: justify; display: table-cell"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">US
FDA. Beyfortus (nirsevimab-alip)
Prescribing&#xA0;Information.</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
&#xA0;</font><font style="font-weight: bold; color: #000000">Adrian
Kemp</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
Company</font></font> <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Secretary</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
PLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
<font style="font-size: 13px">17 July 2023</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By: /s/
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Company Secretary</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
